<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01463436</url>
  </required_header>
  <id_info>
    <org_study_id>Usakti</org_study_id>
    <nct_id>NCT01463436</nct_id>
  </id_info>
  <brief_title>The Effect of Soy Isoflavone Supplementation on Endothelial Function</brief_title>
  <official_title>Study of Soy Isoflavone 100 mg/Day in Postmenopausal Women to Elaborate the Effect of Soy Isoflavone in Endothelial Function and to Reduce Oxidative Stress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Trisakti University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Trisakti University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized double blind controlled trial was conducted to evaluate the effect of daily
      supplementation with soy isoflavone 100 mg/day for 12 months on 182 postmenopausal women aged
      47 to 60 years at subdistrict South Jakarta Indonesia. The study hypothesis was
      supplementation soy isoflavone 100 mg/day for 6 and 12 months can increase endothelial
      function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subject were randomized to the intervention group receiving tablets consisting of 100 mg
      soy isoflavone and calcium carbonate 500 mg and the control group receiving 500 mg calcium
      carbonate for 1 year. This study was carried out 13 months(13 x 28 days).

      There were three outcome measure from this study; vascular cell adhesion molecule-(VCAM-1),
      nitric oxide (NO) and malonyldialdehyde (MDA). The outcome measure will be assessed at three
      times; before soy isoflavone supplementation / the beginning of study,post supplementation 6
      months and 12 months. The outcome will be measured change from baseline in the level of
      VCAM-1, NO and MDA.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the changes levels of endothelial function marker in blood after 13 months supplementation</measure>
    <time_frame>13 months</time_frame>
    <description>this study were measured the change levels of vascular cell adhesion molecule-1 (VCAM-1), nitric oxide (NO) as endothelial function parameter and malonyldialdehide as lipid peroxidation parameter from baseline to 6 months supplementation and from baseline to 13 months supplementation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the changes levels of osteoporosis parameter after 6 months supplementation</measure>
    <time_frame>6 months</time_frame>
    <description>This study have another outcome such as rank ligand, C telopeptide and osteoprotegrin as marker of osteoporosis. We will be measured the changes levels of osteoporosis marker after 6 months supplementation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>soy isoflavone 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the experimental group receiving tablet contain soy isoflavone 100 mg and calcium carbonate 500 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>calcium carbonate 500 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The control group receiving a tablet contains calcium carbonate 500 mg for 6 months and 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>soy isoflavone</intervention_name>
    <description>100 mg soy isoflavone tablet containing genistein 55%, daidzein 39% and glycitein 6% and calcium carbonate 500 mg in the experimental group for 6 months and 12 months</description>
    <arm_group_label>soy isoflavone 100 mg</arm_group_label>
    <other_name>kacang kedelai, soya bean</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>control group</intervention_name>
    <description>the control group receiving tablet contain calcium carbonate 500 mg/day for 6 months and 12 months</description>
    <arm_group_label>calcium carbonate 500 mg</arm_group_label>
    <other_name>plasebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy postmenopausal women

          -  natural cessation 1-10 years

          -  body mass index &lt;=35 kg/m2

          -  not receiving medication and supplement in the previous 6 months

        Exclusion Criteria:

          -  has chronic or terminal disease

          -  severe psychosis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>47 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pusparini Sunarno, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Trisakti University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Trisakti University</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jakarta</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <link>
    <url>http://www.univmed.org</url>
    <description>click here for more information about this tudy</description>
  </link>
  <reference>
    <citation>Hall WL, Rimbach G, Williams CM. isoflavones and endothelial function. Nutrion Research Review 18:123-131, 2005. Vincent A,Fitzpatrick LA. soy Isoflavone: are they useful in menopause? Mayo clinic Proceeding 75:1171-1184, 2000</citation>
  </reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2011</study_first_submitted>
  <study_first_submitted_qc>October 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2011</study_first_posted>
  <last_update_submitted>November 1, 2011</last_update_submitted>
  <last_update_submitted_qc>November 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Trisakti University</investigator_affiliation>
    <investigator_full_name>Dr. dr. Pusparini SpPK</investigator_full_name>
    <investigator_title>Principal investigator, staff of Clinical Pathology Department</investigator_title>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>postmenopausal</keyword>
  <keyword>soy isoflavone supplementation</keyword>
  <keyword>osteoporosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

